Synthetic Bacteria for Therapeutics

키워드

참고문헌 (65)

1. Cameron DE, "A brief history of synthetic biology", Nat Rev. Microbiol, 12, pp.381~390 (2014)
2. Chubukov V, "Synthetic and systems biology for microbial production of commodity chemicals", NPJ Syst. Biol. Appl, 2, pp.16009~ (2016)
3. Paddon CJ, "Semi-synthetic artemisinin : a model for the use of synthetic biology in pharmaceutical development", Nat. Rev. Microbiol, 12, pp.355~367 (2014)
4. Lee SK, "Metabolic engineering of microorganisms for biofuels production : from bugs to synthetic biology to fuels", Curr. Opin. Biotechnol, 19, pp.556~563 (2008)
5. 김송이, "Current Status of Microbial Phenylethanoid Biosynthesis", Journal of Microbiology and Biotechnology, 28(8), pp.1225~1232 (2018), 한국미생물·생명공학회
6. Fangyu Cheng, "Biosynthesis of Chondroitin in Engineered Corynebacterium glutamicum", Journal of Microbiology and Biotechnology, 29(3), pp.392~400 (2019), 한국미생물·생명공학회[DOI]
7. Ruder WC, "Synthetic biology moving into the clinic", Science, 333, pp.1248~1252 (2011)
8. Folcher M, "Synthetic biology advancing clinical applications", Curr. Opin. Chem. Biol, 16, pp.345~354 (2012)
9. Chen YY, "From DNA to targeted therapeutics : bringing synthetic biology to the clinic", Sci. Transl. Med, 3(106), pp.106~ (2011)[DOI]
10. Pedrolli DB, "Engineering microbial living therapeutics : the synthetic biology toolbox", Trends Biotechnol, 37, pp.100~115 (2019)
11. Mays ZJ, "Synthetic biology in probiotic lactic acid bacteria : at the frontier of living therapeutics", Curr. Opin. Biotechnol, 53, pp.224~231 (2018)
12. Jain A, "Microbial synthetic biology for human therapeutics", Syst. Synth. Biol, 6, pp.9~22 (2012)
13. Riglar DT, "Engineering bacteria for diagnostic and therapeutic applications", Nat. Rev. Microbiol, 16, pp.214~225 (2018)
14. Vandenbroucke K, "Orally administered L, lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis", Mucosal Immunol, 3, pp.49~56 (2010)
15. Chien T, "Advances in bacterial cancer therapies using synthetic biology", Curr. Opin. Syst. Biol, 5, pp.1~8 (2017)
16. Chen Z, "Recent development on synthetic biological devices treating bladder cancer", Synth. Syst. Biotechnol, 1, pp.216~220 (2016)
17. Chakravarti D, "Synthetic biology in cellbased cancer immunotherapy", Trends Biotechnol, 33, pp.449~461 (2015)
18. Bhattarai SR, "Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection", Biomaterials, 33, pp.5166~5174 (2012)
19. Din MO, "Synchronized cycles of bacterial lysis for in vivo delivery", Nature, 536, pp.81~85 (2016)
20. Isabella VM, "Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria", Nat. Biotechnol, 36, pp.857~864 (2018)
21. Wegmann U, "Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect", Sci. Rep, 7, pp.2294~ (2017)
22. Slomovic S, "Synthetic biology devices for in vitro and in vivo diagnostics", Proc. Natl. Acad. Sci. USA, 112, pp.14429~14435 (2015)
23. Courbet A, "Bringing next-generation diagnostics to the clinic through synthetic biology", EMBO Mol. Med, 8, pp.987~991 (2016)
24. Kotula JW, "Programmable bacteria detect and record an environmental signal in the mammalian gut", Proc. Natl. Acad. Sci. USA, 111, pp.4838~4843 (2014)
25. Daeffler KN, "Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation", Mol. Syst. Biol, 13, pp.923~ (2017)
26. Winter SE, "Gut inflammation provides a respiratory electron acceptor for Salmonella", Nature, 467, pp.426~429 (2010)
27. Jackson MR, "Human sulfide : quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite", Biochemistry, 51, pp.6804~6815 (2012)
28. Hensel M, "The genetic basis of tetrathionate respiration in Salmonella typhimurium", Mol. Microbiol, 32, pp.275~287 (1999)
29. Heinzinger NK, "Sequence analysis of the phs operon in Salmonella typhimurium and the contribution of thiosulfate reduction to anaerobic energy metabolism", J. Bacteriol, 177, pp.2813~2820 (1995)
30. Chassaing B, "Dextran sulfate sodium (DSS)-induced colitis in mice", Curr. Protoc. Immunol, 104, pp.Unit 15.25~ (2014)
31. Danino T, "Programmable probiotics for detection of cancer in urine", Sci. Transl. Med, 7(289), pp.289ra84~ (2015)
32. Liang Q, "Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer", Clin. Cancer Res, 23, pp.2061~2070 (2017)
33. Brader P, "Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging", Clin. Cancer Res, 14, pp.2295~2302 (2008)
34. Stritzker J, "Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917in live mice", Int. J. Med. Microbiol, 297, pp.151~162 (2007)
35. Gerdes K, "The Parb(Hok Sok)Locus of plasmid-R1-a general-purpose plasmid stabilization system", Bio-Technol, 6, pp.1402~1405 (1988)
36. Derman AI, "Phylogenetic analysis identifies many uncharacterized actin-like proteins(Alps)in bacteria : regulated polymerization, dynamic instability and treadmilling in Alp7A", Mol. Microbiol, 73, pp.534~552 (2009)
37. Claesen J, "Synthetic microbes as drug delivery systems", ACS Synth. Biol, 4, pp.358~364 (2015)
38. Hamady ZZ, "Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus", Gut, 59, pp.461~469 (2010)
39. Duchmann R, "Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease(IBD)", Clin. Exp. Immunol, 102, pp.448~455 (1995)
40. Cook DP, "Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy", Front. Immunol, 8, pp.1961~ (2017)
41. Housley RM, "Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract", J. Clin. Invest, 94, pp.1764~1777 (1994)
42. Abil Z, "Synthetic biology for therapeutic applications", Mol. Pharm, 12, pp.322~331 (2015)
43. Ozdemir T, "Synthetic biology and engineered live biotherapeutics : toward increasing system complexity", Cell Syst, 7, pp.5~16 (2018)
44. Panida Sittipo, "Intestinal microbiota and the immune system in metabolic diseases", The Journal of Microbiology, 56(3), pp.154~162 (2018), 한국미생물학회[DOI]
45. Duan F, "Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model", Proc Natl. Acad. Sci. USA, 107, pp.11260~11264 (2010)
46. Lenz DH, "The small RNA chaperone Hfq and multiple small RNAs control quorum sensing in Vibrio harveyi and Vibrio cholerae", Cell, 118, pp.69~82 (2004)
47. Hwang IY, "Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models", Nat. Commun, 8, pp.15028~ (2017)
48. Saeidi N, "Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen", Mol. Syst. Biol, 7, pp.521~ (2011)
49. Nerup J, "Mechanisms of pancreatic beta-cell destruction in type I diabetes", Diabetes Care, 11(Suppl 1), pp.16~23 (1988)
50. Robert S, "Oral delivery of glutamic acid decarboxylase(GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice", Diabetes, 63, pp.2876~2887 (2014)
51. Tisch R, "Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice", Nature, 366, pp.72~75 (1993)
52. Dosoky NS, "Dietary fatty acids control the species of N-Acylphosphatidylethanolamines synthesized by therapeutically modified bacteria in the intestinal tract", ACS Infect. Dis, 4, pp.3~13 (2018)
53. Chen Z, "Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity", J. Clin. Invest, 124, pp.3391~3406 (2014)
54. Gillum MP, "N-acylphosphatidylethanolamine, a gutderived circulating factor induced by fat ingestion, inhibits food intake", Cell, 135, pp.813~824 (2008)
55. Pinero-Lambea C, "Programming controlled adhesion of E, coli to target surfaces, cells, and tumors with synthetic adhesins", ACS Synth. Biol, 4, pp.463~473 (2015)
56. Park SH, "RGD Peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated salmonella-mediated cancer therapy", Theranostics, 6, pp.1672~1682 (2016)
57. Kramer MG, "Bacterial therapy of cancer : promises, limitations, and insights for future directions", Front. Microbiol, 9, pp.16~ (2018)
58. Hiroshima Y, "Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patientderived orthotopic xenograft(PDOX)", J. Cell Biochem, 115, pp.1254~1261 (2014)
59. Yamamoto M, "Efficacy of tumor-targeting Salmonella A1-R on a melanoma patient-derived orthotopic xenograft(PDOX)nude mouse model", PLoS One, 11, pp.e0160882~ (2016)
60. Bull MJ, "The domestication of the probiotic bacterium Lactobacillus acidophilus", Sci. Rep, 4, pp.7202~ (2014)
61. Dou J, "Synthetic biology and the gut microbiome", Biotechnol. J, 13, pp.e1700159~ (2018)
62. Park W, "Gut microbiomes and their metabolites shape human and animal health", J. Microbiol, 56, pp.151~153 (2018)
63. Probiotics in human health and disease: from nutribiotics to pharmabiotics, "The Journal of Microbiology", 2018, 773~782, pp.한국미생물학회, 10.1007[DOI]
64. Wright O, "Building-in biosafety for synthetic biology", Microbiology, 159, pp.1221~1235 (2013)
65. Wang F, "Synthetic biology : Recent progress, biosafety and biosecurity concerns, and possible solutions", J. Biosafety Biosecurity, 1, pp.22~30 (2019)

관련 논문AI추천